OOIR: Observatory of International Research

Papers

(The TQCC of Circulation-Heart Failure is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy	412
Trends in 30- and 90-Day Readmission Rates for Heart Failure	138
Prevalence and Incidence of Heart Failure Among Urban Patients in China: A National Population-Based Analysis	119
Polypharmacy in Older Adults Hospitalized for Heart Failure	110
Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure	98
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy	83
Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy	66
Invasive Right Ventricular Pressure-Volume Analysis: Basic Principles, Clinical Applications, and Practical Recommendations	59
Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction	59
Clinical Outcomes Associated With Acute Mechanical Circulatory Support Utilization in Heart Failure Related Cardiogenic Shock	55
Defining Shock and Preshock for Mortality Risk Stratification in Cardiac Intensive Care Unit Patients	52
Renal Sympathetic Denervation in Patients With Heart Failure With Preserved Ejection Fraction	49
Excess 30-Day Heart Failure Readmissions and Mortality in Black Patients Increases With Neighborhood Deprivation	47
Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial	46
Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure	46
Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy	42
Metabolomic Profiles and Heart Failure Risk in Black Adults: Insights From the Jackson Heart Study	41
Yellow Wine Polyphenolic Compound Protects Against Doxorubicin-Induced Cardiotoxicity by Modulating the Composition and Metabolic Function of the Gut Microbiota	40
Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure	40
Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review	38
Characterizing Sex Differences in Physical Frailty Phenotypes in Heart Failure	38
Skeletal Muscle Function, Structure, and Metabolism in Patients With Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction	38
Global Differences in Heart Failure With Preserved Ejection Fraction	37
Extracardiac Abnormalities of Preload Reserve	36
Right Heart Failure Following Left Ventricular Device Implantation: Natural History, Risk Factors, and Outcomes: An Analysis of the STS INTERMACS Database	36

NAD ⁺ Redox Imbalance in the Heart Exacerbates Diabetic Cardiomyopathy	36
Disparity in the Setting of Incident Heart Failure Diagnosis	35
Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design	35
Clinical Characteristics and Predictors of In-Hospital Mortality in Patients With Cardiogenic Shock: Results From the RESCUE Registry	35
Better Understanding the Disparity Associated With Black Race in Heart Transplant Outcomes	35
Myocardial Tissue Reverse Remodeling After Guideline-Directed Medical Therapy in Idiopathic Dilated Cardiomyopathy	35
Early Outcomes of Heart Transplantation Using Donation After Circulatory Death Donors in the United States	34
Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort	34
Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy	33
Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves	32
The Value of Passive Leg Raise During Right Heart Catheterization in Diagnosing Heart Failure With Preserved Ejection Fraction	32
Multiparametric Implantable Cardioverter-Defibrillator Algorithm for Heart Failure Risk Stratification and Management: An Analysis in Clinical Practice	31
Association Between Angiotensin Receptor–Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction	31
Intra-Aortic Balloon Pumping in Acute Decompensated Heart Failure With Hypoperfusion: From Pathophysiology to Clinical Practice	31
Cardiogenic Shock From Heart Failure Versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and 1-Year Outcomes	31
Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial	31
Role of Pulmonary Artery Wedge Pressure Saturation During Right Heart Catheterization	30
Alcohol Intake in Patients With Cardiomyopathy and Heart Failure: Consensus and Controversy	30
Pulmonary Hypertension in Congenital Heart Disease: A Scientific Statement From the American Heart Association	30
Racial Inequities in Access to Ventricular Assist Device and Transplant Persist After Consideration for Preferences for Care: A Report From the REVIVAL Study	30
Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation	29
Current Limitations of Invasive Exercise Hemodynamics for the Diagnosis of Heart Failure With Preserved Ejection Fraction	29
Association Between Coffee Intake and Incident Heart Failure Risk	28
Framework to Classify Reverse Cardiac Remodeling With Mechanical Circulatory Support: The Utah-Inova Stages	28
Clinical Characteristics and Outcomes of Adults With a History of Heart Failure Hospitalized for COVID-19	28
Development of Advanced Heart Failure: A Population-Based Study	27
Practice Patterns and Patient Outcomes After Widespread Adoption of Remote Heart Failure Care	27
Cardiolipin Remodeling Defects Impair Mitochondrial Architecture and Function in a Murine Model of Barth Syndrome Cardiomyopathy	27
In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure	26
Current Approach to the Diagnosis of Sarcopenia in Heart Failure: A Narrative Review on the Role of Clinical and Imaging Assessments	26
Mitochondrial Sirtuin-3 (SIRT3) Prevents Doxorubicin-Induced Dilated Cardiomyopathy by Modulating Protein Acetylation and Oxidative Stress	26
Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure	26
Bridging With Extracorporeal Membrane Oxygenation Under the New Heart Allocation System: A United Network for Organ Sharing Database Analysis	26
Exercise Training Protects Against Heart Failure Via Expansion of Myeloid-Derived Suppressor Cells Through Regulating IL-10/STAT3/S100A9 Pathway	26
Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension	25
Race- and Sex-Specific Population Attributable Fractions of Incident Heart Failure	25
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction	24
Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure	24
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial	23
Association of Pulmonary Artery Pulsatility Index With Adverse Cardiovascular Events Across a Hospital-Based Sample	23
Risk-Based Approach for the Prediction and Prevention of Heart Failure	23
Brain-Derived Neurotrophic Factor Improves Impaired Fatty Acid Oxidation Via the Activation of Adenosine Monophosphate-Activated Protein Kinase-ɑ – Proliferator-Activated Receptor-r Coactivator-1ɑ Sig	23
Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial	23
Predictive Accuracy of Heart Failure-Specific Risk Equations in an Electronic Health Record-Based Cohort	22
Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization	22
Novel Trial Design: CHIEF-HF	22
CRD-733, a Novel PDE9 (Phosphodiesterase 9) Inhibitor, Reverses Pressure Overload–Induced Heart Failure	22
Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions	21
Detection of Left Atrial Myopathy Using Artificial Intelligence–Enabled Electrocardiography	21
Transcatheter Mitral Valve Repair in Patients With and Without Cardiac Resynchronization Therapy	21

Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support	21
Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial	21
Transcutaneous Vagus Nerve Stimulation Ameliorates the Phenotype of Heart Failure With Preserved Ejection Fraction Through Its Anti-Inflammatory Effects	21
Estrogen Receptor-β Agonists Modulate T-Lymphocyte Activation and Ameliorate Left Ventricular Remodeling During Chronic Heart Failure	21
Cardiac Microvascular Endothelial Cells in Pressure Overload–Induced Heart Disease	20
Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)–Related Cardiomyopathy: Development of PLN-R14del–Related Cardiomyopathy	20
Novel Small-Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on Energetics	19
Potential Role of Natriuretic Response to Furosemide Stress Test During Acute Heart Failure	19
Intersection of Heart Failure and Pregnancy: Beyond Peripartum Cardiomyopathy	19
Insights Into Myocardial Oxygenation and Cardiovascular Magnetic Resonance Tissue Biomarkers in Heart Failure With Preserved Ejection Fraction	19
Defining a Clinically Important Change in 6-Minute Walk Distance in Patients With Heart Failure and Mitral Valve Disease	19
Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	18
Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan	18
Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8 ⁺ T-Cell Infiltration After Heart Transplantation	18
Intermittent Occlusion of the Superior Vena Cava to Improve Hemodynamics in Patients With Acutely Decompensated Heart Failure: The VENUS-HF Early Feasibility Study	18
Virus-Negative Myopericarditis in Human Coronavirus Infection	18
Multimarker Analysis of Serially Measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, Creatinine, and Prognosis in Acute Heart Failure	17
Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction	17
Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction	17
Safety and Efficacy of Sacubitril/Valsartan in Patients With a Failing Systemic Right Ventricle: A Prospective Single-Center Study	17
Temporal Trends of Heart Failure Hospitalizations in Cardiology Versus Noncardiology Wards According to Ejection Fraction: 16-Year Data From the SwedeHF Registry	17
Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure	17
Improving Fairness in the Prediction of Heart Failure Length of Stay and Mortality by Integrating Social Determinants of Health	17
Durable Mechanical Circulatory Support in Patients With Amyloid Cardiomyopathy	17
MiR-150 Attenuates Maladaptive Cardiac Remodeling Mediated by Long Noncoding RNA MIAT and Directly Represses Profibrotic Hoxa4	17
Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis	17
FGF21 (Fibroblast Growth Factor 21) Defines a Potential Cardiohepatic Signaling Circuit in End-Stage Heart Failure	17
Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease	16
Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial	16
Right Ventricular and Right Atrial Function Are Less Compromised in Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction: A Comparison With Pulmonary Arterial Hypertensio	16
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan	16
Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States	16
Targeted Therapies in Pediatric and Adult Patients With Hypertrophic Heart Disease: From Molecular Pathophysiology to Personalized Medicine	16
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials	16
Skeletal Muscle Mass Recovery Early After Left Ventricular Assist Device Implantation in Patients With Advanced Systolic Heart Failure	15
The RAISE Trial: A Novel Device and First-in-Man Trial	15
How Patients With Heart Failure Perform Daily Life Activities	15
Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry	15
Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry	15
Peripheral Venous Pressure-Assisted Exercise Stress Echocardiography in the Evaluation of Pulmonary Hypertension During Exercise in Patients With Suspected Heart Failure With Preserved Ejection Fracti	15
Automated E-Counseling for Chronic Heart Failure	15
Obesity and Outcomes Following Cardiogenic Shock Requiring Acute Mechanical Circulatory Support	15
Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure	15
Impairments in Blood Pressure Regulation and Cardiac Baroreceptor Sensitivity Among Patients With Heart Failure Supported With Continuous-Flow Left Ventricular Assist Devices	15
Association of Sedentary Time and Incident Heart Failure Hospitalization in Postmenopausal Women	15
Changing Demographics, Temporal Trends in Waitlist, and Posttransplant Outcomes After Heart Transplantation in the United States: Analysis of the UNOS Database 1991–2019	15
Safety of Endomyocardial Biopsy in New-Onset Acute Heart Failure Requiring Veno-Arterial Extracorporeal Membrane Oxygenation	15
Mineralocorticoid Receptor in Smooth Muscle Contributes to Pressure Overload–Induced Heart Failure	15
Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through β3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial	15
Protocolized Natriuresis-Guided Decongestion Improves Diuretic Response: The Multicenter ENACT-HF Study	14
ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy	14
Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure	14
Clinical Heart Failure Among Patients With and Without Severe Mental Illness and the Association With Long-Term Outcomes	14
Exception Status Listing in the New Adult Heart Allocation System: A New Solution to an Old Problem?	14
Liberation From Venoarterial Extracorporeal Membrane Oxygenation: A Review	14
Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop	14
Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure	14
Participation in a Heart Failure Clinical Trial	14
Response by Elliott et al to Letter Regarding Article, “Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy”	14
Testosterone, Hypogonadism, and Heart Failure	14
Sarcopenic Obesity Is Associated With Reduced Cardiorespiratory Fitness Compared With Nonsarcopenic Obesity in Patients With Heart Failure With Reduced Ejection Fraction	14
False-Positive ^99m Technetium-Pyrophosphate Scintigraphy in Two Patients With Hypertrophic Cardiomyopathy	14
Clinical Profile and Health Disparities in a Multiethnic Cohort of Patients With Hypertrophic Cardiomyopathy	13
The Association of Protein Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction	13
Patient-Specific Computational Fluid Dynamics Reveal Localized Flow Patterns Predictive of Post–Left Ventricular Assist Device Aortic Incompetence	13
Use of a Pulmonary Artery Pressure Sensor to Manage Patients With Left Ventricular Assist Devices	13
Intoxicated Donors and Heart Transplant Outcomes: Long-Term Safety	13
Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure and Preserved Ejection Fraction	13
Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy	13
Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF	12
Impact of Race on Clinical Outcomes After Implantation With a Fully Magnetically Levitated Left Ventricular Assist Device: An Analysis From the MOMENTUM 3 Trial	12
Temporal Trends and Clinical Trial Characteristics Associated With the Inclusion of Women in Heart Failure Trial Steering Committees: A Systematic Review	12
Increased Risk of Congestive Heart Failure Following Carbon Monoxide Poisoning	12
Validating an Idiopathic Dilated Cardiomyopathy Diagnosis Using Cardiovascular Magnetic Resonance: The Dilated Cardiomyopathy Precision Medicine Study	12
Renal Denervation for Patients With Heart Failure	12
Remodeling of the Purkinje Network in Congestive Heart Failure in the Rabbit	12
Management of Hypertension in Patients With Ventricular Assist Devices: A Scientific Statement From the American Heart Association	12
Avoiding Catastrophe	12
A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure With Preserved Ejection Fraction	12
Targeting Preload in Heart Failure: Splanchnic Nerve Blockade and Beyond	12

Inflammatory Glycoprotein 130 Signaling Links Changes in Microtubules and Junctophilin-2 to Altered Mitochondrial Metabolism and Right Ventricular Contractility	12
Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical Trials of Patients With Heart Failure	12
Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure	11
Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction	11
Trends in Characteristics and Outcomes in Primary Heart Failure Hospitalizations Among Older Population in the United States, 2004 to 2018	11
Medical Therapy for Functional Mitral Regurgitation	11
Endothelial-Mesenchymal Transition in Heart Failure With a Preserved Ejection Fraction	11
Right Ventricular Architectural Remodeling and Functional Adaptation in Pulmonary Hypertension	11
Metabolically Healthy/Unhealthy Overweight/Obesity Associations With Incident Heart Failure in Postmenopausal Women	11
Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial	11
Socioeconomic Disparities in Referral for Invasive Hemodynamic Evaluation for Advanced Heart Failure: A Nationwide Cohort Study	11
Neighborhood Socioeconomic Disadvantage and Hospitalized Heart Failure Outcomes in the American Heart Association Get With The Guidelines-Heart Failure Registry	11
Race, Social Determinants of Health, and Length of Stay Among Hospitalized Patients With Heart Failure: An Analysis From the Get With The Guidelines-Heart Failure Registry	11
Impact of Patient-Reported Outcome Measurement in Heart Failure Clinic on Clinician Health Status Assessment and Patient Experience: A Substudy of the PRO-HF Trial	11
Disparities in Hospital Length of Stay Across Race and Ethnicity Among Patients With Heart Failure	11
Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group	11
Exposure to Arterial Hyperoxia During Extracorporeal Membrane Oxygenator Support and Mortality in Patients With Cardiogenic Shock	11
Machine Learning-Based Prediction of Myocardial Recovery in Patients With Left Ventricular Assist Device Support	11
Outcomes With Peripheral Venoarterial Extracorporeal Membrane Oxygenation for Suspected Acute Myocarditis: 10-Year Experience From the Extracorporeal Life Support Organization Registry	11
Optical Coherence Tomography in Cardiac Allograft Vasculopathy	11